Table 2 Radiographic and Pathological Responses

From: Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial

Radiographic response n = 30

No.(%)

ORR

9(30.0)

 PR

9(30.0)

 SD

2(6.7)

 PD

19(63.3)

DCR

11(36.6)

Pathological Response n = 15

No.(%)

Response

10(66.7)

 pCR

4(26.7)

 MPR

6(40.0)

No Response

5(33.3)

  1. ORR objective response rate, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate, pCR pathological complete response, MPR major pathological response.
Back to article page